McDermott advised Antabio in the raising of € 7.3M Series-A Financing to Develop Novel Treatments against Drug-Resistant Gram-Negative Infections
PARIS (October 16, 2017) –International law firm McDermott Will & Emery has advised Antabio SAS (“Antabio”), a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, in relation to a €7.3M series-A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.
The funding will be used to accelerate the development, up to completion of Phase 1 clinical trials, of Antabio’s novel inhibitor of bacterial metallo ß-lactamases (“MBLIs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections.
This financing complements the recent CARB-X grant of up to $8,9 million awarded to Antabio in July 2017 to support the company’s Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.
The team advising Antabio was led by Anthony Paronneau (Partner), supported by Laetitia de Dinechin and Chloé Huertas.
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.